Study of Anti-Inflammatory Effect of Dipyridamole by Evaluation Inflammatory Cells and Histopathology in Rat: Airway Models
Study of Anti-Inflammatory Effect of Dipyridamole by Evaluation Inflammatory Cells and Histopathology in Rat: Airway Models
Ali D. Nashmi1*, Jawad K. Hasan1, Manal A. Ibrahim2
ABSTRACT
Pneumonitis, another name for lung inflammation, can be caused by respiratory infections, exposure to pollutants or allergens from the air, and lung conditions such as chronic bronchitis or asthma. An inhibitor of phosphodiesterase enzymes 3 and 5, dipyridamole is a conventional antiplatelet drug that increases adenosine. The purpose of this study was to investigate whether dipyridamole plays a role as an anti-inflammatory to improve airway inflammation. A total of 24 healthy rats (albino, male), were weighted (150-300 g), were divided into four groups, each group consisting of six rats; Group A rats were given oral distal water and was considered a negative control group. Group B rats received distal water orally with ovalbumin (ova) sensitization, which was considered a positive control group. Group C rats were given dipyridamole (26.4 mg / kg) orally with sensitization to the ova. Group D rats received prednisolone (4.12mg/kg) orally with sensitization to the ova. Subsequently, the right lung was lavage, by insertion of a tracheal cannula, three times with 10 ml of normal saline (NS 0.9%) at 37 °C and the broncho alveolar lavage fluid (BALF) was sent for laboratory evaluations and the left lung was incised for histopathological evaluation. Data analysis indicated that a substantial decrease in total white blood cell counts (WBC) was observed (p-value <0.05) and cells including (neutrophils, mononuclear) in BALF of rats treated with dipyridamole (group C) and prednisolone (group D) compared to positive control (group B), but reduction in eosinophils cells in dipyridamole treated group C was non significant (p-value>0.05) there was also an improvement in histological characteristics regarding bronchial dilatation and improvement in the alveolar sac and modification of inflammatory cells in lung tissues in dipyridamole treated rats (group C) and prednisolone treated (group D) was observed in contrast to ovalbumin (ova) sensitized rats (group B). Collectively, dipyridamole has the ability to decrease inflammation to a lower limit in the airways in rats through its ability to decrease total and differential WBCs in BALF.
To share on other social networks, click on any share button. What are these?
